Pharmazon has received a minority investment from a private investor
The shareholders of Pharmazon have sold the company to a private investor.
Pharmazon is a B2B distributor of OTC and parapharmacy products to French pharmacies. Its core business is to buy products directly from laboratories, negotiating good conditions and selling them online through a modern website which looks similar to Amazon.com.
The company's shareholders are the CEO and General Director.
Oaklins' team in France advised the seller in this transaction.
Talk to the deal team
Related deals
A group of Chilean investors has acquired Farmacias Ahumada
A group of Chilean investors has acquired Farmacias Ahumada S.A. from Walgreens Boots Alliance.
Learn moreShield Therapeutics has completed a fundraising
Shield Therapeutics plc has raised funds to bolster the expansion of ACCRUFeR®, the sole FDA-approved therapy for iron deficiency and to drive the business. Additionally, it positions the company for further investments.
Learn moreHaydale Graphene Industries has completed a fundraising
Haydale Graphene Industries PLC has raised funds to continue to develop the ongoing commercialization of its proprietary HDPlas® plasma functionalization process.
Learn more